Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Eiger Biopharmaceuticals (EIGR) has issued an announcement.
Eiger BioPharmaceuticals, Inc. has filed for Chapter 11 bankruptcy, leading to Nasdaq’s decision to delist the company’s stock due to non-compliance with listing rules. The company won’t appeal the delisting and anticipates its stock to commence trading on the over-the-counter market under the new symbol EIGRQ on April 11, 2024. Additionally, Dr. Jeffrey S. Glenn has resigned from the board, with no disputes influencing his departure.
For detailed information about EIGR stock, go to TipRanks’ Stock Analysis page.